News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Genmab A/S Announces Results From Zalutumumab Phase III Study of Refractory Head and Neck Cancer Patients
March 8, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
COPENHAGEN, Denmark, March 8, 2010 (GLOBE NEWSWIRE) -- Summary: Genmab announces top-line results from a study of zalutumumab in refractory head and neck cancer patients who failed platinum-based chemotherapy.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
MORE ON THIS TOPIC
HIV
Gilead Looks To Simplify HIV Treatment By Combining Two Leading Drugs in One Pill
November 14, 2025
·
2 min read
·
Tristan Manalac
RNA editing
Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal
November 13, 2025
·
3 min read
·
Annalee Armstrong
Obesity
Zealand Freezes Mid-Stage Obesity Asset To Focus on More Differentiated Drugs
November 13, 2025
·
2 min read
·
Tristan Manalac
Neuroscience
Alkermes Pushes Narcolepsy Program to Phase III With ‘Highly Competitive’ Mid-Stage Data
November 13, 2025
·
2 min read
·
Tristan Manalac
